Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo

Journal of Clinical Psychopharmacology

Volumn 19, Issue 5, 1999, Pages 435-443

  Tollefson, Gary D ^a   Dellva, Mary Anne ^a   Mattler, Carole A ^a   Kane, John M ^b,i   Wirshing, Donna A ^c   Kinon, Bruce J ^a   Ames, Donna ^d   Cohn, Cal K ^e   Daniel, David G ^f   Clark, Scott C ^g   Horne, Robert L ^h   Levine, Robert ^h   Miller, Marvin ^j   Nemeroff, Charles B ^k   Reinstein, Michael R ^l   Smith, Thomas E ^m  

^a ELI LILLY AND COMPANY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Cohn Center ^*  (United States)

^f Washington Clinical Research Center   (United States)

^g NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^h Hillside Hospital ^*  (United States)

ⁱ ZUCKER HILLSIDE HOSPITAL   (United States)

^j Larue D Carter Memorial Hospital   (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l The University of Hospitals   (United States)

^m WEILL CORNELL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; PLACEBO;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG EFFICACY; FEMALE; HUMAN; HYPERSALIVATION; MALE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; TREATMENT PLANNING; WITHDRAWAL SYNDROME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032842391     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199910000-00007     Document Type: Article

References (51)

1. Kane J, Honingfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic, a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
2. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992:63:51-70.
3. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57[suppl 11]:12-25.
4. Buchanan RW. Clozapine efficacy and safety. Schizophr Bull 1995;21:579-791.
5. Gaertner HJ, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology (Berl) 1989;99:S97-S100.
6. Grohmann R, Ruther E, Sassin N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology (Berl) 1989;99:S101-S104.
7. Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160[suppl 17]:54-9.
8. Shore D. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995;21:333-8.
9. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 1991;52: 346-8.
10. Borison RL, Diamond BI, Sinha D, Gupta RP. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988;24:260-3.
11. Ekblom B, Eriksson K, Lindstrom LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 1984;83:293-4.
12. Eklund K. Supersensitivity and clozapine withdrawal [letter]. Psychopharmacology (Berl) 1987;91:135.
13. Palia SS, Clarke EJ. Clozaril withdrawal syndrome. Psychiatr Bull 1993;17:374-5.
14. Parsa MA, al-Lahham YH, Ramirez LF, Meltzer HY. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 1993;13:154-5.
15. Perenyi A, Kuncz E, Bagdy G. Early relapse after sudden withdrawal or dose reduction of clozapine [letter]. Psychopharmacology (Berl) 1985;86:244.
16. Stanilla JK, de Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997;58:252-5.
17. Tanriverdi N, Yazici K. Immediate recurrence of psychotic symptoms after discontinuation of clozapine: a case report. Biol Psychiatry 1996;39:814-5.
18. de Leon J, Stanilla JK, White AO, Simpson GM. Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry 1994;55:119-20.
19. Meltzer HY, Lee MA, Ranjan R, Mason EA, Cola PA. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology (Berl) 1996;124:176-87.
20. Dickson R, Williams R, Dalby JT. Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation [letter]. Can J Psychiatry 1994;39:184.
21. Lacey RL, Preskorn SH, Jerkovich GS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics [letter]? Am J Psychiatry 1995;152:1401.
22. Radford JM, Brown TM, Borison RL. Unexpected dystonia while changing from clozapine to risperidone. J Clin Psychopharmacol 1995;15:225-6.
23. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
24. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104.
25. Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptor by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992;77:87-93.
26. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW. Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995;120:67-74.
27. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical"antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-51.
28. Coding Symbol and Thesaurus for Adverse Event Terminology (COSTART). Rockville, MD: U.S. Department of Health and Human Services, 1990.
29. Guy W, ed. ECDEU assessment manual for psychopharmacology. Publication number ADM 76-338. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976:217-22.
30. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) manual. North Tonawanda, NY: Multi-Health Systems, 1986.
31. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
32. Folstein MF, Folstein SE, McHugh P. Mini-mental state: a practical method of grading the cognitive state of the patient for the physician. J Psychiatr Res 1975;12:189-95.
33. SAS Institute Inc. SAS/STAT user's guide. 1st and 2nd vols. 4th ed. 6th version. Cary, NC: SAS Institute Inc., 1990.
34. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin uptake inhibitors: a literature review. J Clin Psychiatry 1997;58:291-7.
35. 19F magnetic resonance spectroscopy. Am J Psychiatry 1998;155:380-4.
36. Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, Kurtz NM, Cutler NR. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophren Bull 1996;22:591-5.
37. Meltzer HY. Clozapine withdrawal: serotonergic or dopaminergic mechanisms? Arch Gen Psychiatry 1997;54:760-1.
38. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 1997;129:79-84.
39. Gardner DM, Baldessarini RJ, Benzo J, Zarate CA, Tohen M. Switching between clozapine and risperidone treatment. Can J Psychiatry 1997;42:430-1.
40. Still DJ, Dorson PG, Crimson ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-4.
41. Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1995;52: 1071-2.
42. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 1995;120:365-8.
43. 4-like receptors. Neuropsychopharmacology 1997;17:186-96.
44. Verghese C, de Leon J, Neui C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996;39:135-8.
45. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19.
46. de Leon J, Henighan V, Stanilla JK, Simpson GM. Clozapine levels after clozapine discontinuation. J Clin Psychopharmacol 1996; 16:193-4.
47. Seeman P. In reply. Arch Gen Psychiatry 1997;54:762-3.
48. Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
49. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 1993;54[suppl]:49-61.
50. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997;58[suppl]:17-22.
51. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-84.